Cabot Co. (NYSE:CBT) Shares Bought by Creative Planning

Creative Planning raised its stake in Cabot Co. (NYSE:CBT) by 24.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,614 shares of the specialty chemicals company’s stock after purchasing an additional 2,103 shares during the period. Creative Planning’s holdings in Cabot were worth $975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. CWM LLC raised its position in Cabot by 60.6% in the 2nd quarter. CWM LLC now owns 416 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 157 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Cabot by 33.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 475 shares of the specialty chemicals company’s stock valued at $48,000 after purchasing an additional 119 shares in the last quarter. 1620 Investment Advisors Inc. purchased a new position in shares of Cabot in the 2nd quarter valued at about $49,000. Mather Group LLC. purchased a new position in shares of Cabot in the 2nd quarter valued at about $58,000. Finally, nVerses Capital LLC purchased a new position in shares of Cabot in the 2nd quarter valued at about $64,000. Institutional investors and hedge funds own 93.18% of the company’s stock.

Insider Buying and Selling

In other Cabot news, CEO Sean D. Keohane sold 25,617 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total transaction of $2,601,406.35. Following the completion of the sale, the chief executive officer now directly owns 331,174 shares of the company’s stock, valued at approximately $33,630,719.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Cabot news, CFO Erica Mclaughlin sold 16,390 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $104.24, for a total transaction of $1,708,493.60. Following the completion of the sale, the chief financial officer now directly owns 59,814 shares of the company’s stock, valued at approximately $6,235,011.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sean D. Keohane sold 25,617 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total value of $2,601,406.35. Following the sale, the chief executive officer now directly owns 331,174 shares of the company’s stock, valued at $33,630,719.70. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,939 shares of company stock worth $7,308,812 in the last quarter. 3.07% of the stock is owned by insiders.

Cabot Trading Down 0.1 %

NYSE:CBT opened at $110.81 on Friday. The stock’s 50 day moving average price is $103.67 and its 200 day moving average price is $98.71. The company has a market capitalization of $6.12 billion, a PE ratio of 14.03, a P/E/G ratio of 1.01 and a beta of 1.19. The company has a quick ratio of 1.45, a current ratio of 2.22 and a debt-to-equity ratio of 0.72. Cabot Co. has a 52-week low of $65.10 and a 52-week high of $113.12.

Cabot (NYSE:CBT) last released its quarterly earnings results on Monday, August 5th. The specialty chemicals company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Cabot had a return on equity of 26.99% and a net margin of 12.05%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.42 EPS. On average, research analysts anticipate that Cabot Co. will post 7.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CBT. JPMorgan Chase & Co. increased their price objective on Cabot from $95.00 to $105.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. UBS Group dropped their price objective on Cabot from $103.00 to $98.00 and set a “neutral” rating on the stock in a report on Tuesday, August 6th. Finally, StockNews.com downgraded Cabot from a “strong-buy” rating to a “buy” rating in a report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $101.75.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.